This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange fell a fraction to 1,000.63 Friday, ending the week down 19.22 points. Today we have another hopeful medical marijuana deal to discuss, courtesy of the brothers Steve and Gary Mathiesen. Their halted capital pool shell, Strachan Resources Ltd. (SCN), plans to acquire Lotus Ventures Inc., which has an option to buy a medical marijuana grow-op with a licence issued under an old government policy (MMAR) that is being phased out and replaced with licences issued under the new policy, MMPR. There are currently 13 MMPR licences and although Strachan's QT target, Lotus Ventures, has submitted an application to operate its grow-op under the MMPR policy, it has not yet received a licence.

The shell will acquire Lotus Ventures for an unstated number of shares. Strachan must also surrender and cancel 1.5 million escrow shares, change its name to that of its target and transfer to the Canadian Securities Exchange. It will then inherit the target's option to buy the medical marijuana grow-op, and be responsible for investing $250,000 and issuing two million shares, both payable in stages.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS